Tamoxifen-d5 (Synonyms: ICI 47699-?d5; (Z)-Tamoxifen-?d5; trans-Tamoxifen-?d5) |
Catalog No.GC48124 |
타목시펜-d5(ICI 47699-d5)는 타목시펜으로 표시된 중수소입니다. 타목시펜(ICI 47699)은 경구 활성 선택적 에스트로겐 수용체 조절제(SERM)입니다. 타목시펜은 강력한 Hsp90 활성화제이며 Hsp90 분자 샤페론 ATPase 활성을 향상시킵니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 157698-32-3
Sample solution is provided at 25 µL, 10mM.
Tamoxifen-d5 contains five deuterium atoms at the 3, 3, 4, 4, and 4 positions. It is intended for use as an internal standard for the quantification of tamoxifen by GC- or LC-MS. Tamoxifen is a selective estrogen receptor (ER) modulator, evoking tissue-dependent effects. It is an antagonist of ER action in breast tissue and breast cancer cells and is reported to be effective in the treatment of early breast cancer to prevent tumor growth.1,2 Importantly, tamoxifen has been reported to act as an ER agonist in bone and blood vessels, helping to minimize osteoporosis and reduce the risk of cardiovascular disease in post-menopausal women.3 Also, tamoxifen is a partial ER agonist in uterine tissues and is reported to increase the risk of endometrial carcinoma.4
1.Horwitz, K.B., and McGuire, W.L.Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processingJ. Biol. Chem253(22)8185-8191(1978) 2.Clarke, M., Collins, R., Davies, C., et al.Tamoxifen for early breast cancer: An overview of the randomised trialsLancet351(9114)1451-1467(1998) 3.Tonetti, D.A., and Jordan, V.C.Targeted anti-estrogens to treat and prevent diseases in womenMol. Med. Today2(5)218-223(1996) 4.Jordan, V.C., and Assikis, V.J.Endometrial carcinoma and tamoxifen: Clearing up a controversyClin. Cancer Res.1(5)467-472(1995)
Average Rating: 5
(Based on Reviews and 21 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *